A California-based pharmaceutical company called Sorento Therapeutics has confirmed that it has discovered an antibody that can protect the human body from coronavirus and expel it from the body within four days.
The company announced earlier Friday its discovery of the antibody "STI-1499", which it said could inhibit the "corona virus by 100%," adding that treatment could be available months before the vaccine reaches the market.
The founder and CEO of Sorrento Therapeutics, said Dr. Henry J., to media, "We want to confirm there is a cure, and we have a solution that works 100 percent."
"If you have a neutral antibody in your body, you don't need social separation, and the quarantine can be ended without fear," he says.
The company released details of its preclinical research on Friday, announcing that it had found an antibody that provided "100% inhibition of SARS-2 infection in healthy cells four days after incubation."
These results resulted in a pre-clinical study that still needs to be reviewed, meaning that it is in the laboratory and not a real person, but it still represents a promising development as the company continues to work on the production of a "cocktail" of antibodies that can provide protection against SARS - CoV-2 even if mutations appear in the virus.
Sorento says she believes this antibody, called STI-1499, has emerged among the billions of antibodies that the company examined from a large-scale human antibody library and demonstrated its ability to completely block the interaction of SARS-CoV-2 proteins with human target cell receptors.
This means that it prevents the virus from attaching to the healthy host cell, which leads to incubation and infection.
The nature of the effectiveness of the antibody made Sorrento to include it in the cocktail that it develops as the first antibody, as this cocktail consists of a large number of different antibodies that appear effective in preventing the virus attached to the body, and in order to provide multiple and effective protection methods even if the virus mutates in It is transferred from one person to another, or within the same person.
Soretto has developed what it calls the "Covid Protective Shield" through a powerful mixture of different antibodies that provide protection against different strains of the virus, but the company says it will also continue to develop the STI-1499 antibody on its own.
The company is already in discussions with regulators about how to expedite the development of this potential treatment, and it is also increasing its production capacity with the goal of producing up to a million doses while simultaneously seeking FDA approval for use.
It is noteworthy that it is not likely that any treatment or vaccine "magic bullet" in the treatment of SARS - Covid 2 or Covid - 19, but this is still a promising development, and is subject to clinical and treatment trials.